Skip to main content

Table 2 Short-term efficacy of 9 evaluable patients with exploratory multi-line therapy

From: The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China

Short-term efficacy Monotherapy, n (%) Combined Treatment, n (%)
Complete response (CR) 0 (0) 0 (0)
Partial response (PR) 2 (33.3) 0 (0)
Stable disease (SD) 1 (16.7) 1 (33.3)
Progression disease (PD) 3 (50.0) 2 (66.7)
Objective response rate (ORR) 2/6 (33.3) 0 (0)
Disease control rate (DCR) 3/6 (50.0) 1/3 (33.3)
  1. The table above showed the short-term efficacy of 9 evaluable patients with exploratory multi-line therapy including 6 patients with niraparib monotherapy and 3 patients with combined treatment. Short-term efficacy was classified by modified Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)